

Neonatal Exhaled Breath Sampling for Infrared Spectroscopy: Biomarker Analysis

Nadia Feddahi, Lea Hartmann, Ursula Felderhoff-Müser, Susmita Roy, Renée Lampe, and Kiran Sankar Maiti*



Cite This: *ACS Omega* 2024, 9, 30625–30635




Read Online

ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: Monitoring health conditions in neonates for early therapeutic intervention in case deviations from physiological conditions is crucial for their long-term development. Due to their immaturity preterm born neonates are dependent on particularly careful physical and neurological diagnostic methods. Ideally, these should be noninvasive, noncontact, and radiation free. Infrared spectroscopy was used to analyze exhaled breath from 71 neonates with a special emphasis on preterm infants, as a noninvasive, noncontact, and radiation-free diagnostic tool. Passive sample collection was performed by skilled clinicians. Depending on the mode of respiratory support of infants, four different sampling procedures were adapted to collect exhaled breath. With the aid of appropriate reference samples, infrared spectroscopy has successfully demonstrated its effectiveness in the analysis of breath samples of neonates. The discernible increase in concentrations of carbon dioxide, carbon monoxide, and methane in collected samples compared to reference samples served as compelling evidence of the presence of exhaled breath. With regard to technical hurdles and sample analysis, samples collected from neonates without respiratory support proved to be more advantageous compared to those obtained from intubated infants and those with CPAP (continuous positive airway pressure). The main obstacle lies in the significant dilution of exhaled breath in the case of neonates receiving respiratory support. Metabolic analysis of breath samples holds promise for the development of noninvasive biomarker-based diagnostics for both preterm and sick neonates provided an adequate amount of breath is collected.



The discernible increase in concentrations of carbon dioxide, carbon monoxide, and methane in collected samples compared to reference samples served as compelling evidence of the presence of exhaled breath. With regard to technical hurdles and sample analysis, samples collected from neonates without respiratory support proved to be more advantageous compared to those obtained from intubated infants and those with CPAP (continuous positive airway pressure). The main obstacle lies in the significant dilution of exhaled breath in the case of neonates receiving respiratory support. Metabolic analysis of breath samples holds promise for the development of noninvasive biomarker-based diagnostics for both preterm and sick neonates provided an adequate amount of breath is collected.

INTRODUCTION

Health monitoring of preterm born, as well as term born neonates with complications such as perinatal asphyxia or sepsis, remains a major challenge for clinicians, despite recent improvements in survival rates due to advancements in obstetrics and neonatal intensive care.^{1–3} In preterms, challenges arise from numerous problems that may affect their developmental progress.^{4–6} In particular, clinicians face a significant challenge in the complex interplay between prenatal maternal health factors and potential immaturity complications such as bronchopulmonary dysplasia (BPD), inflammatory events (sepsis, necrotizing enterocolitis—NEC) or intraventricular hemorrhage (IVH), and socioeconomic factors.^{7–9} The risk for cerebral palsy (CP) or other neurological disorders for example, inversely correlates with gestational age (GA); meaning that the earlier children are born, the higher the risk for neurological impairment.^{10,11} Despite the use of sophisticated methods for monitoring health and diagnostic scores, it is almost impossible to predict the clinical or neurological outcomes of these children during their perinatal inpatient stay. For example, although, the risk of

infantile CP is related to GA, usually it is diagnosed at the age of 1–2 years.^{12–14} This is because children can be in a transitional phase during their development, in which it is not yet clear whether permanent disability will develop or whether the developmental delay will normalize.^{15,16} Therefore, monitoring the health status of these neonates is crucial to effectively address arising problems potentially affecting their development.^{17–19} In addition, it is important to make an early developmental prognosis, both to initiate supportive interventions early and to communicate this prognosis to parents.^{20,21} To overcome these challenges, the ideal health monitoring approach would be noninvasive, noncontact, and radiation-free diagnostic methods to avoid unnecessary stress, risks, and side effects for the children.

Received: March 20, 2024

Revised: June 17, 2024

Accepted: June 24, 2024

Published: July 2, 2024






Figure 1. Collection procedures of exhaled breath samples from neonates are depicted with the help of a model. Passive breath sample collection for neonates under various conditions, including (a) spontaneously breathing neonate, (b) air from the incubator with neonate, (c) neonate with CPAP delivered via "infant flow" as respiratory support, and (d) intubated neonate.

In this regard, metabolites-based diagnosis certainly would be an attractive option,^{22,23} since many metabolites can be collected noninvasively via, urine, faeces, exhaled breath, etc.^{24,25} It is an established fact that metabolites, which are byproducts of biochemical reactions in the living cell, carry specific cellular information.^{26,27} Analyzing the chemical compositions of these metabolites allows insights into the body's internal chemistry, facilitating better monitoring of the body's state,^{22,28} as well as an indication of diseases that remain asymptomatic in their initial stages.^{29–31} As bioprobe, exhaled breath stands out as a particularly promising source of metabolites for clinical diagnosis,³² primarily due to its noninvasiveness, patient-friendly nature, and rapid processing capabilities. Since the 1970s, numerous studies have investigated breath-based metabolites in the adult population.³³ The primary reason for selecting adults as the test group is the convenience of sample collection. Currently, individuals being tested still need to exhale directly into the measurement system or a storage device. However, there remains significant debate surrounding sample collection, even for adults.³⁴ Certain demographics, such as infants or individuals who are immobile, weak, or in intensive care, face challenges in performing the required exhalation maneuvers for breath analysis. Recent research has made strides in addressing these challenges. In one study, breath samples were collected from 16 infants using Nalophan bags.³⁵ In another study, the exhaled breath of neonates was directly collected from the respiratory support system using a sampling pump.³⁶ Furthermore, beyond newborns, research has expanded to include the analysis of volatile organic compounds (VOCs) in the exhaled breath of pregnant sheep. This exploration holds significant promise for identifying pregnancies complicated by intra-amniotic infections.³⁷

Various experimental techniques, e.g., different mass spectrometry (MS) techniques, infrared (IR) spectroscopy, electronic nose (e-nose), etc. are rapidly developing to reveal gaseous metabolites and have already demonstrated their contributions to breath research.^{38,39} It is worth noting that MS techniques currently play the most significant role in breath research, identifying hundreds of VOCs with an impressive sensitivity down to 100 ppt (parts per trillion).⁴⁰ However, the complex and underdeveloped sample preparation process in MS leads to accuracy issues, which raises doubts about its reliability for medical diagnosis.⁴¹ Furthermore, MS devices are costly and bulky in size. In contrast, e-nose devices are more cost-effective and compact.^{42,43} They

use an array of chemical sensors to mimic the human olfactory system.⁴⁴ However, their "black box" nature has resulted in varying outcomes across research groups. Moreover, e-nose devices are not suitable for the identification of metabolites.⁴⁵

Compared to mass spectrometry and e-nose devices, infrared spectroscopy offers several advantages in the identification and quantification of molecular compositions from a mixture of molecules in the gas. It uses the most fundamental molecular properties, e.g., molecular vibrations, as a probe to identify the molecule through structural analysis.^{46–49} Infrared light is used to stimulate molecular bonds and consequently, the absorption of light during their vibrational motion is recorded by an infrared detector. This process leads to the generation of a distinctive set of spectral features for each molecule in the acquired infrared spectra. In the realm of clinical spectroscopy, these distinct spectral features are commonly referred to as "fingerprints" of the molecule.^{50,51} The precise characteristics, including the position, intensity, and morphology of these molecular fingerprints, play a crucial role in advancing metabolite-based infrared diagnostics.^{52,53}

Notably, infrared spectroscopy has already demonstrated its efficacy in identifying biomarkers for various diseases in the adult population.^{14,29} Here, we hypothesize that infrared spectroscopy for breath biomarker analysis can also contribute to neonatal health monitoring, provided a feasible means of collecting an adequate quantity of exhaled breath can be established. We outline a procedure for the collection of neonatal exhaled breath and the corresponding measurement techniques.

■ EXPERIMENTAL METHOD

Sample Collection. Preterms or critically ill newborn infants are kept in a meticulously controlled environment, akin to a pristine clean room. The use of any equipment is strictly limited. Therefore, all spectroscopic measurements were conducted offline. The current state-of-the-art method for breath sample collection and storage for infrared diagnosis involves using a single-use Tedlar bag (Supelco Tedlar Bags, LOT#: 10311LC19C).⁵⁴ The sample collection bags are equipped with a valve through which a participant can actively blow exhaled air, just as simple as blowing a balloon. In the case of newborns, sample collection needed to be performed passively, representing the major challenge for the development of this noninvasive, noncontact, metabolites-based diagnostic tool. Further adjustments were required depending




Figure 2. Sample population according to the GA of neonates. A blue color bar plot illustrates the mean GA for each group, with the lowest and highest GAs noted on the bars. Similarly, the red bars depict the lowest, highest, and mean BW. The left side scale corresponds to the mean GA, while the right side scale corresponds to the mean BW.

on the type of respiratory support (invasive, noninvasive CPAP) and also depending on the type of care (incubator, baby cot). The collection procedures are presented in Figure 1 using a model.

Study Design. This prospective cohort single-center study was approved by the Ethics Committee of the Faculty of Medicine at the Technical University of Munich (Reference Number: 146/21 S-EB) and the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (Reference Number: 21-10068-BO), and conducted in accordance with the Declaration of Helsinki. All experimental protocols, as well as procedures related to patients' data privacy and personal interests, received approval. Before collecting breath samples, the parents of the neonates were duly informed about the study and provided their written consent.

Following parental informed consent 50 preterm and 21 healthy term born at the University Hospital Essen between 01/04/2022 and 24/01/2023 with gestational age (GA) between 24_{+1} (the subscript stands for days) and 40_{+2} weeks (mean GA 32_{+6} weeks) and birth weight (BW) between 425 and 4270 g (mean BW 1985.6 g) were included in this study (Figure 2). The total number of samples was subdivided by GA into five subgroups. Neonates born at or beyond 37_{+0} weeks were categorized as "term born". Breath samples of 21 healthy term born infants with an average GA of 39_{+3} weeks (born between 37_{+1} and 40_{+2} weeks) and an average BW of 3294 g (born with a BW between 2690 and 4270 g) were collected. The second group consisted of "late preterm" neonates born between 35_{+0} and 36_{+6} weeks ($n = 7$, mean GA 35_{+2} (35_{+0} to 36_{+5})) and mean BW of 2585 g (ranging from 1700 to 3520 g). The "early preterm" group included infants born between 32_{+0} and 34_{+6} weeks ($n = 12$, mean GA 33_{+3} (32_{+1} to 34_{+5})) and mean BW of 1756 g (ranging from 1300 to 2240 g). The subsequent group was "very preterm", comprising neonates born between 28_{+0} and 31_{+6} weeks ($n = 16$, mean GA 30_{+3} (28_{+0} to 31_{+6})) mean BW 1487 g (ranging from 745 to 2400 g). In the "extreme preterm" category we considered infants born $<28_{+0}$ weeks ($n = 15$ mean GA of 25_{+3} (24_{+1} to 27_{+6}), mean BW of 806 g (ranging from 425 to 1135 g).

Neonates Breathing Spontaneously (S). Irrespective of the GA, the majority of the neonates in the study group breathed spontaneously. For them breath sampling was performed with a 50 ml syringe (Original Perfusor Syringe 50 ml, LOT: 21E18D8004) held as near as possible between mouth and nose, without touching the neonate's skin, and slowly aspirating the exhaled air (see Figure 1a). The collected breath sample was injected into the Tedlar bag via a needle through the intended valve. This procedure was repeated 20 times to collect about 1 Liter of sample from each neonate. An equivalent volume of ambient air was collected in a separate Tedlar bag to serve as a point of comparison (reference air) for the samples collected from spontaneous breathing.

Neonates Requiring Incubator Care. For small preterm born neonates incubator care is essential due to their immature thermoregulation system.⁵⁵ To investigate the influence of exhaled breath in the entire incubator's air, a few samples (reference sample) were collected far from the infant's nose (see Figure 1b). Otherwise, samples were collected close to the nose. All collections were performed using a 50 mL syringe and followed the same procedure as described above in (a).

Neonates on CPAP (Infant Flow) as Respiratory Support (CPAP). Continuous Positive Airway Pressure (CPAP) is a method of applying positive airway pressure by continuously delivering air into the respiratory tract.⁵⁶ This technique is employed to ensure a consistent pressure level, thereby ensuring the continual patency of the airway in individuals who are naturally breathing (S). Samples were collected directly from the exhalation tube of the system by holding a 50 mL syringe near the tube opening and slowly aspirating the air (see Figure 1c). Subsequently, the sample collection procedure was followed as explained above. Collected air from the inhalation tube served as a reference sample for neonates on CPAP.

Neonates on Invasive Ventilation (Dräger Babylog VN500, IT). Invasive ventilation involves the use of a ventilator to deliver air into the airways through an endotracheal tube, maintaining a specific pressure level.⁵⁷ In the study period, only one neonate required invasive respiratory support. The sample was collected by directly connecting the Tedlar bag

over an interponate to the closed system of the respirator (see Figure 1d).

All collected samples were classified according to the GA and type of respiratory support illustrated in Figure 3. It is important to note that a single syringe was used for each neonate, to prevent sample contamination.




Figure 3. Classification of collected samples according to the GA of the neonates as well as their life and respiratory support. The subscript in GA indicates the days, e.g., GA = 36₊₆ weeks mean 36 weeks and 6 days.

Sample Preparation. All samples collected at University Hospital Essen were stored at 4 °C for a maximum of 7 days prior to transfer to the Department of Physics, Ludwig-Maximilians University of Munich for spectroscopic analysis.

Samples were transported in well-sealed polystyrene boxes with cold packs. Samples arrived within 24 h and were measured immediately upon arrival. It is important to note that the majority of samples were transferred within 2–3 days of collection, therefore, they were analyzed 2–4 days after collection. In such a short time frame, we do not anticipate any leakage or degradation of the samples. This was confirmed by a separate study involving 10 aliquoted samples from healthy adults. All samples were stored at 4 °C and analyzed up to 30 days after collection. There was no significant change in the molecular concentration of breath metabolites observed until day 20. However, a slight decrease (approximately 20% by the 30th day) in CO₂ concentration was noted thereafter. Notably, there were practically no deviations observed for the other molecules analyzed, which are larger in size than CO₂.

Compared to the other breath sample analysis techniques, infrared spectroscopy requires a minimal sample preparation process. The primary challenge encountered when applying infrared spectroscopy to exhaled breath is the substantial presence of water within the samples. However, a recent advancement in water suppression technique for gaseous biofluids has introduced a promising avenue for conducting infrared spectroscopic analyses on gaseous biofluids.⁵⁸ To prepare samples amenable to infrared spectroscopic analysis, a self-built water suppression system was employed. Figure 4 provides a schematic overview of the water suppression technique, coupled with the spectroscopic measurement unit. The details of the system and its working principle were reported earlier.⁵⁸ In brief, the sample preparation technique consisted of two major units, namely, (1) a sample collector and (2) a sample preparation unit. (1) The sample collector system was designed in such a way that it could accept gaseous samples as well as the headspace of liquid biofluids. Prior to




Figure 4. Diagram of the experimental scheme for gaseous biofluid analysis by infrared spectroscopy. It consists of three major parts: (1) Collection—in this part, breath or headspace of liquid biofluids is collected; (2) Preparation—a water-suppressed sample is prepared for infrared spectroscopy when gaseous biofluids are passing through the “Water Condenser”; and (3) Analysis—water suppressed gaseous sample is collected in a multipass gas cell and measured with an FTIR spectrometer.

Table 1. Number of Samples for Each Sampling Method in Which Metabolites Are Detected^a

sampling methods		metabolites					
		carbon dioxide		carbon monoxide		methane	modified
		detected	elevated	detected	elevated		methane
spontaneous		55	55	55	47	55	15
incubator	CPAP	15	15	15	11	15	2
	Infantflow	1	1	1	1	1	1

^aThe elevation of absorption strength of metabolites was analyzed with respect to the corresponding reference spectra.

sample injection into the sample collector, the entire sample path was evacuated (down to a pressure level of 10^{-5} mbar) using two vacuum pumps. This process effectively eliminates any residual contamination from previous measurements. Breath samples were transferred to the empty sample collector by releasing the valve. (2) The sample preparation unit was composed of essential components, including a water condenser and both heat and refrigerated circulators. The water condenser was designed as a sealed metal chamber housing a 12-m-long copper tube coiled into a spiral configuration. This copper tube served as the conduit for transferring the breath sample from the sample collector to a measurement cell. Prior to its passage through the water condenser, the chamber was meticulously cooled to a temperature of -60 °C using a refrigerated circulator. Once the water condenser reached this frigid temperature, the breath sample was allowed to flow through the spiral copper tube at a precisely controlled rate of 3 mL per second. During this transit through the cold copper tubing, a substantial amount of water vapor was effectively removed from the sample. Remarkably, an impressive water vapor reduction factor exceeding 2500 was achieved when the sample passed through the water condenser at -60 °C. Subsequently, the water-suppressed gas-phase biofluid was transferred to the multipass sample cell. Following each experimental run, the copper tube undertook a cleaning procedure by heating up the chamber to 45 °C with the heat circulator and vacuum pumps.

Spectroscopic Measurements. All the spectroscopic measurements of breath samples were performed using an FTIR spectrometer (Vertex 70, Bruker Optics GmbH, Germany). The spectrometer operated within a spectral range of 500 – 4000 cm^{-1} and utilized a 4-m optical path length along with a 2-L “White cell” (Bruker Optics GmbH, Germany) to hold gaseous samples for spectroscopic analysis. The absorption spectra of breath samples were captured by a liquid nitrogen-cooled MCT detector. For all measurements, a 0.5 cm^{-1} spectral resolution was used. To reduce the noise, 100 spectra were collected and averaged for each sample. The spectrometer demonstrated a sensitivity of 10 parts per billion (ppb) for VOCs within the range of moderate water absorption.

Spectroscopic Data Analysis. The absorption spectra of breath samples were analyzed by component analysis.^{59,60} Initially, significant spectral features were searched from the infrared spectra of breath. Gas-phase molecular spectra were fitted with the observed spectral features in the breath sample using least-squares fitting in order to find out the best agreement.⁵⁹ Usually, gas-phase molecular spectra were collected from commercial databases (e.g., PNNL,⁶¹ HITRAN,⁶² NIST⁶³) or acquiring spectra experimentally as well as theoretically by quantum chemistry calculations.^{59,64}

RESULTS AND DISCUSSIONS

The primary goal of our study was to establish the reliability of sample collection from neonates from different gestational age groups. It is a well-known fact that human exhaled air volume strongly depends on body weight.⁶⁵ Therefore, a high dynamic range of exhaled air is expected from different sample groups as the body weight of the neonates largely varies. While we analyzed individually the collected exhaled breath samples of 71 neonates, for demonstration purposes, only one case from each group is presented graphically. The summary of our results is presented in Table 1.

IR Spectra of Room Air. To validate the reliability of our exhaled breath sampling methods, we initiated a comparative study involving the analysis of infrared spectra from four distinct sources: the ambient air, exhaled breath of neonates without respiratory support (Figure 1a), samples from the exhalation tube (CPAP, invasive ventilation) (Figure 1c and d), and air collected from incubators with neonate inside (Figure 1b). The primary challenge we encountered was assessing the variability within these four sample types. To address this, we initially concentrated on examining the ambient air. The reason behind this is obvious. Since our specific target group was neonates, we collected samples in close proximity to their nose and mouth, ensuring no physical contact and minimizing the risk of contamination. Consequently, a substantial amount of ambient air was inadvertently mixed with the breath samples. To conduct an accurate analysis of these mixed samples, it became imperative to segregate the contribution of ambient air. Therefore, acquiring a comprehensive understanding of the characteristics of ambient air became an essential step in the study.

A representative infrared spectrum of water-suppressed ambient air is depicted in Figure 5, revealing three prominent absorption peaks centered at approximately 670 , 2350 , and 3600 cm^{-1} . These absorption peaks correspond to distinct vibrational modes of carbon dioxide (CO_2).⁶² CO_2 is a




Figure 5. Infrared absorption spectra of room air. Inset is the 10⁴ times magnification of the same spectra at around 3000 cm^{-1} .




Figure 6. Infrared absorption spectra of ambient air, incubator's air (with neonate), and exhaled air of a neonate with spontaneous (S) respiration, inlet and outlet air of a CPAP system. Spectra are zoomed around the absorption spectra of carbon dioxide.

prevalent component of atmospheric air, existing at a relatively high concentration of around 400 ppm (parts per million).⁶⁶ Furthermore, humans also emit endogenous CO₂ when exhaling, contributing to the atmospheric CO₂ content. Fortunately, separating these two sources of CO₂ is a straightforward task through digital subtraction techniques.⁵⁹ However, extracting specific biochemical information in the body by CO₂ is rather challenging, since a majority of biochemical processes in the human body produce CO₂. While CO₂ may not be highly informative for health monitoring, its significance in our study is elucidated in the subsequent section.

The initially unremarkable spectra became significant when spectra were zoomed along the “absorbance axis.” This amplification, spanning three to four orders of magnitude, unveils numerous molecular signatures that provide a deeper insight into the body's state. To illustrate, a three-order magnification centered around the spectral position at 3000 cm⁻¹ exposes a distinct spectral pattern attributed to methane, comprising its well-defined P, Q, and R branches⁵⁸ (visible in the inset of Figure 5). Additionally, several other molecular signatures were detected, and their explanations were described in subsequent sections.

Identification of Breath of Neonates. The next question is whether passively collected breath samples obtained from different groups of neonates contained sufficient information for health monitoring through infrared spectroscopy. “Passively collected” means that these samples consisted of a combination of exhaled breath and ambient air.

To address this question, a comprehensive study was performed using samples from various groups. It is well-established that many biochemical reactions within cells generate CO₂ as a byproduct. In general, CO₂ is produced

when carbohydrates and fats are metabolized.^{67,68} The cardiovascular system plays a crucial role in transporting CO₂ from tissues to the alveolar membrane of the lungs. Due to the concentration gradient of CO₂ between the alveolar air and the blood vessels in the alveolar membrane, leading to the diffusion of CO₂ into the alveolar air. Consequently, exhaled breath contains a significantly higher concentration of CO₂ compared to inhaled air. The variability of these samples was assessed by measuring CO₂ levels, which serve as a reliable indicator.⁶⁹ Given that endogenous CO₂ significantly contributes to the composition of breath metabolites, the amount of CO₂ content above the ambient (reference) CO₂ level served as a practical measure of the proportion of exhaled breath in the collected sample.

In our practical analysis, we compared the strength of CO₂ absorption in various sample types. Typically, the most pronounced CO₂ infrared absorption peak is observed at around 2350 cm⁻¹. Figure 6 demonstrates the zoomed-in spectra depicting the characteristics of CO₂ absorption in different sample types including ambient air, air from an incubator (with an infant present), a sample from the inlet and outlet of CPAP and a sample of exhaled air collected from a baby without respiratory support.

It is noteworthy that the reference air varies depending on the respiratory support provided to neonates. In the simplest scenario, room air is considered as the reference for neonates without respiratory assistance. In Figure 6, the gray plot illustrates the reference spectra for nonrespiratory supported neonates. Incubators typically equipped with a controlled oxygen supply, result in lower CO₂ levels compared to room air. To establish the reference for neonates in an incubator, we collected air samples distant from their mouths (refer to Figure 1b), represented by the green spectrum. As anticipated, the

CO₂ absorption strength was lower than the room air. For neonates on respiratory support, inhaled air is precisely controlled with elevated oxygen levels, and the inlet air served as the reference for these cases. This reference sample exhibits significantly lower CO₂ compared to other references, as depicted by the blue line in Figure 6. These diverse reference air samples showcase distinct CO₂ concentrations, forming the basis for further analysis.

Notably, samples collected near the neonate's mouth exhibited the strongest CO₂ absorption spectra. The CO₂ absorption strength for this sample is 80% stronger than the corresponding reference, attributed to the neonate's exhaled breath. To ensure the consistency of the sample collection process, we collected five consecutive samples from a single neonate, and the CO₂ absorption strength remained consistent in each sample, indicating uniform and replicable collections.

The inset of Figure 6 displays the infrared spectra of the inlet and outlet air of CPAP. A more than 80% increase in CO₂ levels in the outlet confirms the presence of neonate exhaled air. This affirms the capability of our sampling method and detection technique in accurately discerning neonate breath samples.

To estimate the minimum distance from mouth for effective sample collection, we conducted a dilution series with a healthy adult volunteer. An exponential drop in absorption strength with the distance was observed. Notably, when the sample was collected 10 cm distant from the nose, the CO₂ absorption strength decreased by 50% compared to the collection closer to the nose without touching the skin. Here it is noted that samples were collected in the exhaled air flow direction.

Carbon Monoxide. To additionally support our investigations on collected exhaled breath from neonates, we explored the absorption spectra of carbon monoxide (CO). Typically, carbon monoxide is present in the atmosphere at an extremely low concentration, measuring less than 100 ppb.⁷⁰ This concentration varies based on factors such as population density, civilization, industrial activity, and geographical location. However, in the exhaled breath of healthy adults, a significant amount of CO exists as an endogenous metabolite produced due to oxidative stress in the lungs and inflammatory tissue injury.⁷¹

In the realm of infrared spectroscopy, the characteristic absorption spectrum of CO is typically located around 2170 cm⁻¹. In human breath infrared spectra, the CO absorption feature is often obscured by the overlapping water absorption spectra. However, in our experiment, the robust water suppression techniques allowed us to clearly visualize the absorption spectra of CO. We have presented the absorption spectra of various sample types at CO absorption spectral region in Figure 7. In case of ambient air (red line), no measurable CO was observed. However, prominent spectral features of CO were observed for exhaled breath from neonates breathing spontaneously (S), intubated and invasively ventilated (IT) neonates, and neonates on noninvasive ventilation (CPAP) as respiratory support. This finding provides additional supportive evidence for the efficacy of our sampling method.

Methane. Methane is one of the greenhouse gases present in the atmosphere. During inhalation, each individual inhales methane from ambient air, and a similar amount is expected in exhaled breath. In general, methane concentrations tend to be notably higher in a subset of the adult population, affirming its




Figure 7. Infrared absorption spectra of ambient air along with exhaled breath from neonates with spontaneous (S) respiration, intubated (IT) and CPAP as respiratory support. The spectra are magnified around the absorption feature of carbon monoxide.

endogenous origin.⁷² This increased methane concentration in exhaled breath has been attributed to the presence of methanogenic bacteria,⁷³ and it can vary among individuals based on factors such as ethnic background, diet, gut bacterial flora, and intestinal transit time.⁷⁴

To the best of our knowledge, there is currently no research available on methane levels in the exhaled breath of neonates. Therefore, this study represents the inaugural investigation into methane concentrations in the exhaled breath of neonates. In Figure 8, we present infrared spectra of methane obtained




Figure 8. Infrared absorption spectra of ambient air, the sample from a neonate with CPAP respiratory support, air from an incubator, and exhaled air of a neonate with spontaneous (S) respiration. Spectra are zoomed around the absorption feature of methane.

from the ambient air, exhaled air of a neonate (see Figure 1a), air from the outlet of infantflow tube (see Figure 1c), and the air from the incubator with neonate (see Figure 1b). It is important to note that the methane molecules were not isolated from the sample. Instead, the absorption spectral region of methane was magnified and depicted in the figure. Notably, all of these spectra exhibit striking similarities in terms of absorption strength. To provide a more detailed view of the spectral strength, we have zoomed in on the spectral peak at 2948 cm⁻¹, which is shown as an inset in Figure 8. It is evident that the spectral peaks from all four samples perfectly overlap, indicating the absence of endogenous methane in the exhaled breath of these two particular neonates. However, it is worth noting that a minor increase up to 20% in methane absorption strength was observed in a couple of neonates within our study group. Determining the source of this slight




Figure 9. (a–d) Infrared spectra of breath in the spectral region of methane for four different neonates. The spectral feature of methane is modified due to the presence of unknown endogenous metabolites.

elevation in methane absorption spectra remains a challenge. In general, it is observed that methane concentrations can increase 2–10 times in the adult population.⁷⁵

Although a minor variation in methane concentration is noted in 19 out of 71 neonates, it is insufficient to draw any meaningful conclusions regarding the gut bacterial flora. Instead, we observe a significant modification in the spectral characteristics of methane from a few neonates. For instance, Figure 9 displays spectra around 3000 cm^{-1} for exhaled breath from four individual infants. In Figure 9a, the spectra's baseline appears largely uniform, as expected. When there is no overlap with other molecular spectra, methane spectra typically exhibit a flat baseline. However, in Figure 9b, a slight modification is detected in the P-branch of the methane spectra. A previous study documented a similar change in methane spectra.⁷⁶ Nevertheless, in the current investigation, we do not have the opportunity to further explore the underlying causes of this spectral modification.

A similar modification is observed in both Figure 9c and Figure 9d, but its impact is significantly more pronounced than in Figure 9b. Interestingly, these two samples originated from twins. Regardless of the underlying reason for this spectral characteristic, both infants exhibit the same concentration of this specific metabolite. A similar spectral feature was observed in exhaled breath of 18 out of the 71 neonates. Notably, the spectral intensity of this attribute varies among individuals, suggesting that all 18 neonates possess this specific metabolite, although in varying concentrations.

Table 1 provides an overview of three metabolites discussed in this article. While we have identified many more metabolic signatures in the exhaled breath of neonates, methane, CO_2 , and CO are consistently present in all samples. However, the elevation of absorption strength is not uniform. In particular, no elevation of carbon monoxide was observed for a few

samples, both in the case of spontaneous breathing and CPAP respiratory support. It is possible that those neonates exhaled significantly small amounts of carbon monoxide, falling below our detection limit. Another possibility is the nonuniformity in the sample collection. Despite the efforts of two skilled clinicians, the challenging health conditions of neonates may have affected the consistency of sample collection. This underscores the necessity to reassess our sample collection procedure to ensure uniformity, and we are actively working on refining the technique for this purpose. Furthermore, the analysis technique and identification of breath biomarkers can be further improved by employing GC-MS analysis in conjunction with the present FTIR technique.

CONCLUSIONS

To the best of our knowledge, we demonstrate the first study on exhaled breath of 71 preterm and term born newborns using infrared spectroscopy. Four different methods were explored for collecting breath samples, depending on the type of respiratory support required.

Among the four sampling techniques investigated, the method involving sample collection between the nose and mouth was the simplest way of sample collection which yielded the most promising results. Exhaled breath and reference sample collections from neonates with respiratory supports seem more challenging compared to spontaneously breathing neonates. It is imperative to reassess and refine the sampling procedure.

By utilizing the infrared molecular spectral characteristics of carbon dioxide and carbon monoxide, the study demonstrated the effectiveness of the sample collection techniques in gathering exhaled breath from neonates. Although a slight increase in methane concentration was observed in the exhaled

breath of 19 neonates, it is not enough to conclude its endogenous origin. However, the modification of methane spectra in 18 out of 71 neonates unambiguously manifests the exhaled breath sample collection. The exact cause of this spectral modification remains unidentified. Nevertheless, it is intriguing to note that this feature was consistently present in the case of twins, suggesting a potential shared physiological characteristic among them.

The developed breath collection method would definitely be extremely valuable for monitoring the health of newborns. Consequently, we believe this technique will empower us to identify biomarkers, with a particular focus on those associated with neurological diseases that may remain asymptomatic at a very early age.

AUTHOR INFORMATION

Corresponding Author

Kiran Sankar Maiti – TUM School of Natural Sciences, Department of Chemistry, Technical University of Munich, 85748 Garching, Germany; Max-Planck-Institut für Quantenoptik, 85748 Garching, Germany; orcid.org/0000-0002-7337-7541; Phone: +49 89 289 13438; Email: kiran.maiti@tum.de; Fax: +49 89 289 13416

Authors

Nadia Feddahi – Center for Translational and Neurobehavioural Sciences CTNBS, Department of Pediatrics I, Neonatology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany

Lea Hartmann – Center for Translational and Neurobehavioural Sciences CTNBS, Department of Pediatrics I, Neonatology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany

Ursula Felderhoff-Müser – Center for Translational and Neurobehavioural Sciences CTNBS, Department of Pediatrics I, Neonatology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany

Susmita Roy – Research Unit of the Buhl-Strohmaier Foundation for Cerebral Palsy and Pediatric Neuroorthopaedics, Department of Orthopaedics and Sports Orthopaedics, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany

Renée Lampe – Research Unit of the Buhl-Strohmaier Foundation for Cerebral Palsy and Pediatric Neuroorthopaedics, Department of Orthopaedics and Sports Orthopaedics, TUM School of Medicine and Health, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany; Markus Würth Professorship, Technical University of Munich, 81675 Munich, Germany

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsomega.4c02635>

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

R.L. acknowledges the funding from Buhl-Strohmaier and Würth Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. K.S.M. acknowledges partial financial support from DFG. The authors thank all parents for their

support of this study. The authors also thank Ferenc Krausz and Mihaela Žigman for their support with experimental facilities and ideas for the improvement of the study. Frank Fleischmann is acknowledged for technical support.

REFERENCES

- (1) Lawn, J. E.; et al. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. *Lancet* **2023**, *401*, 1707–1719.
- (2) Gallagher, K.; Shaw, C.; Parisaei, M.; Marlow, N.; Aladangady, N. Attitudes About Extremely Preterm Birth Among Obstetric and Neonatal Health Care Professionals in England. *JAMA Network Open* **2022**, *5*, No. e2241802.
- (3) Behrman, R. E., Butler, A. S., Eds. *Preterm Birth*; National Academies Press: Washington, D.C., 2007.
- (4) Zhao, Y.; Liu, G.; Liang, L.; Yu, Z.; et al. Relationship of plasma MBP and 8-oxo-dG with brain damage in preterm. *Open Medicine* **2022**, *17*, 1674–1681.
- (5) Iroh Tam, P.-Y.; Bendel, C. M. Diagnostics for neonatal sepsis: current approaches and future directions. *Pediatr. Res.* **2017**, *82*, 574–583.
- (6) Ashorn, P.; et al. Small vulnerable newborns-big potential for impact. *Lancet* **2023**, *401*, 1692–1706.
- (7) Linsell, L.; Malouf, R.; Morris, J.; Kurinczuk, J. J.; Marlow, N. Risk Factor Models for Neurodevelopmental Outcomes in Children Born Very Preterm or With Very Low Birth Weight: A Systematic Review of Methodology and Reporting. *American Journal of Epidemiology* **2017**, *185*, 601–612.
- (8) Tataranno, M. L.; Vijlbrief, D. C.; Dudink, J.; Benders, M. J. N. L. Precision Medicine in Neonates: A Tailored Approach to Neonatal Brain Injury. *Front. Pediatr.* **2021**, *9* DOI: [10.3389/fped.2021.634092](https://doi.org/10.3389/fped.2021.634092).
- (9) Felderhoff-Müser, U.; Hüning, B. Biomarker und Neuro-monitoring zur Entwicklungsprognose nach perinataler Hirnschädigung. *Monatsschrift Kinderheilkunde* **2022**, *170*, 688–703.
- (10) Marlow, N.; Wolke, D.; Bracewell, M. A.; Samara, M. Neurologic and Developmental Disability at Six Years of Age after Extremely Preterm Birth. *New England Journal of Medicine* **2005**, *352*, 9–19.
- (11) Spittle, A. J.; Orton, J. Cerebral palsy and developmental coordination disorder in children born preterm. *Seminars in Fetal and Neonatal Medicine* **2014**, *19*, 84–89. Long-term outcome for the tiniest or most immature babies.
- (12) Ellenberg, J. H.; Nelson, K. B. Early Recognition of Infants at High Risk for Cerebral Palsy: Examination at Age Four Months. *Developmental Medicine & Child Neurology* **1981**, *23*, 705–716.
- (13) Herskind, A.; Greisen, G.; Nielsen, J. B. Early identification and intervention in cerebral palsy. *Developmental Medicine & Child Neurology* **2015**, *57*, 29–36.
- (14) Maiti, K. S.; Roy, S.; Lampe, R.; Apolonski, A. Breath indeed carries significant information about a disease. Potential biomarkers of cerebral palsy. *J. Biophotonics* **2020**, *13*, No. e202000125.
- (15) McIntyre, S.; Morgan, C.; Walker, K.; Novak, I. Cerebral Palsy—Don't Delay. *Developmental Disabilities Research Reviews* **2011**, *17*, 114–129.
- (16) te Velde, A.; Morgan, C.; Novak, I.; Tantsis, E.; Badawi, N. Badawi Early Diagnosis and Classification of Cerebral Palsy: An Historical Perspective and Barriers to an Early Diagnosis. *J. Clin. Med.* **2019**, *8*, 1599.
- (17) Meem, M.; Modak, J. K.; Mortuza, R.; Morshed, M.; Islam, M. S.; Saha, S. K. Biomarkers for diagnosis of neonatal infections: A systematic analysis of their potential as a point-of-care diagnostics. *J. Glob. Health* **2011**, *1* (2), 201–209.
- (18) Celik, I. H.; Hanna, M.; Canpolat, F. E.; Pammi, M. Diagnosis of neonatal sepsis: the past, present and future. *Pediatr. Res.* **2022**, *91* (2), 337–350.
- (19) Mahwasane, T.; Maputle, M. S.; Simane-Netshisaulu, K. G.; Malwela, T. Provision of Care to Preterm Infants at Resource Limited

Health Facilities of Mopani District, South Africa. *Annals of Global Health* **2020**, *86*, 10.

(20) Boland, R. A.; Davis, P. G.; Dawson, J. A.; Doyle, L. W. What are we telling the parents of extremely preterm babies? *Australian and New Zealand Journal of Obstetrics and Gynaecology* **2016**, *56*, 274–281.

(21) Patel, R. M.; Rysavy, M. A.; Bell, E. F.; Tyson, J. E. Survival of Infants Born at Periviable Gestational Ages. *Clinics in Perinatology* **2017**, *44*, 287–303.

(22) Maiti, K. S.; Lewton, M.; Fill, E.; Apolonski, A. Human beings as islands of stability: Monitoring body states using breath profiles. *Sci. Rep.* **2019**, *9*, 16167.

(23) Qiu, S.; Cai, Y.; Yao, H.; Lin, C.; Xie, Y.; Tang, S.; Zhang, A.; et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. *Sig. Transduct. Target Ther.* **2023**, *8* DOI: 10.1038/s41392-023-01399-3.

(24) Shirasu, M.; Touhara, K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. *Journal of Biochemistry* **2011**, *150*, 257.

(25) Drabińska, N.; Flynn, C.; Ratcliffe, N.; Belluomo, I.; et al. A literature survey of all volatiles from healthy human breath and bodily fluids: the human volatilome. *Journal of Breath Research* **2021**, *15*, 034001.

(26) Metzler, D. E. *Biochemistry: The Chemical Reactions of Living Cells*; Academic Press: New York, 2003.

(27) Ahern, K. *Biochemistry and Molecular Biology: How Life Works*; Teaching Company, LLC: Chantilly, VA, 2019.

(28) Huber, M.; Kepesidis, K. V.; Voronina, L.; Bozic, M.; Trubetskov, M.; Harbeck, N.; Krausz, F.; Zigman, M.; et al. Stability of person-specific blood-based infrared molecular fingerprints opens up prospects for health monitoring. *Nat. Commun.* **2021**, *12*, 1511.

(29) Maiti, K. S.; Fill, E.; Strittmatter, F.; Volz, Y.; Sroka, R.; Apolonski, A. Towards reliable diagnostics of prostate cancer via breath. *Sci. Rep.* **2021**, *11*, 18381.

(30) Maiti, K. S.; Fill, E.; Strittmatter, F.; Volz, Y.; Sroka, R.; Apolonski, A. Standard operating procedure to reveal prostate cancer specific volatile organic molecules by infrared spectroscopy. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* **2024**, *304*, 123266.

(31) Gowda, G. N.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. Metabolomics-based methods for early disease diagnostics. *Expert Review of Molecular Diagnostics* **2008**, *8*, 617–633.

(32) Beauchamp, J. D.; Davis, C.; Pleil, J. D. *Breathborne Biomarkers and the Human Volatilome*; Elsevier: New Amsterdam, 2020.

(33) Pauling, L.; Robinson, A. B.; Teranishi, R.; Cary, P. Quantitative Analysis of Urine Vapor and Breath by Gas-Liquid Partition Chromatography. *Proc. Natl. Acad. Sci. U. S. A.* **1971**, *68*, 2374–2376.

(34) Sukul, P.; Schubert, J. K.; Zanaty, K.; Trefz, P.; Sinha, A.; Kamysek, S.; Miekisch, W.; et al. Exhaled breath compositions under varying respiratory rhythms reflects ventilatory variations: translating breathomics towards respiratory medicine. *Sci. Rep.* **2020**, *10* DOI: 10.1038/s41598-020-70993-0.

(35) Decrue, F.; Singh, K. D.; Gisler, A.; Awchi, M.; et al. Combination of Exhaled Breath Analysis with Parallel Lung Function and FeNO Measurements in Infants. *Anal. Chem.* **2021**, *93*, 15579–15583.

(36) Romijn, M.; van Kaam, A. H.; Fenn, D.; Bos, L. D.; et al. Exhaled Volatile Organic Compounds for Early Prediction of Bronchopulmonary Dysplasia in Infants Born Preterm. *Journal of Pediatrics* **2023**, *257*, 113368.

(37) Ophelders, D. R. M. G.; Boots, A. W.; Hütten, M. C.; Al-Nasiry, S.; Jellema, R. K.; Spiller, O. B.; van Schooten, F.-J.; Smolinska, A.; Wolfs, T. G. A. M. Screening of Chorioamnionitis Using Volatile Organic Compound Detection in Exhaled Breath: A Pre-clinical Proof of Concept Study. *Front. Pediatr.* **2021**, *9*, 488.

(38) Maiti, K. S. Non-Invasive Disease Specific Biomarker Detection Using Infrared Spectroscopy: A Review. *Molecules* **2023**, *28*, 2320.

(39) Pham, Y. L.; Beauchamp, J. Breath Biomarkers in Diagnostic Applications. *Molecules* **2021**, *26*, 5514.

(40) Li, C.; Chu, S.; Tan, S.; Yin, X.; Jiang, Y.; Dai, X.; Gong, X.; Fang, X.; Tian, D.; et al. Towards Higher Sensitivity of Mass Spectrometry: A Perspective From the Mass Analyzers. *Front. Chem.* **2021**, *9* DOI: 10.3389/fchem.2021.813359.

(41) Hanna, G. B.; Boshier, P. R.; Markar, S. R.; Romano, A. Accuracy and Methodologic Challenges of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis. *JAMA Oncology* **2019**, *5*, No. e182815.

(42) Karakaya, D.; Ulucan, O.; Turkan, M. Electronic Nose and Its Applications: A Survey. *Int. J. Autom. Comput.* **2020**, *17*, 179–209.

(43) Ye, Z.; Liu, Y.; Li, Q. Recent Progress in Smart Electronic Nose Technologies Enabled with Machine Learning Methods. *Sensors* **2021**, *21*, 7620.

(44) Kwon, O. S.; Song, H. S.; Park, S. J.; Lee, S. H.; An, J. H.; et al. An Ultrasensitive, Selective, Multiplexed Superbioelectronic Nose That Mimics the Human Sense of Smell. *Nano Lett.* **2015**, *15*, 6559–6567.

(45) Di Natale, C.; Paolesse, R.; Martinelli, E.; Capuano, R. Solid-state gas sensors for breath analysis: A review. *Anal. Chim. Acta* **2014**, *824*, 1–17.

(46) Wilson, E.; Decius, J.; Cross, P. *Molecular Vibrations: The Theory of Infrared and Raman Vibrational Spectra*. *Dover Books on Chemistry Series*; Dover Publications: New York, 1980.

(47) Maiti, K. S. Vibrational spectroscopy of Methyl benzoate. *Phys. Chem. Chem. Phys.* **2015**, *17*, 19735–19744.

(48) Roy, S.; Maiti, K. S. Structural sensitivity of CH vibrational band in methyl benzoate. *Spectrochim. Acta Mol. Biomol. Spectrosc.* **2018**, *196*, 289–294.

(49) Maiti, K. S. Ultrafast vibrational coupling between C–H and C = O band of cyclic amide 2-Pyrrolidinone revealed by 2DIR spectroscopy. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* **2020**, *228*, 117749.

(50) Buchan, E.; Kelleher, L.; Clancy, M.; Stanley Rickard, J. J.; Oppenheimer, P. G. Spectroscopic molecular-fingerprint profiling of saliva. *Anal. Chim. Acta* **2021**, *1185*, 339074.

(51) Maiti, K. S. Two-dimensional Infrared Spectroscopy Reveals Better Insights of Structure and Dynamics of Protein. *Molecules* **2021**, *26*, 6893.

(52) Takamura, A.; Watanabe, K.; Akutsu, T.; Ozawa, T. Soft and Robust Identification of Body Fluid Using Fourier Transform Infrared Spectroscopy and Chemometric Strategies for Forensic Analysis. *Sci. Rep.* **2018**, *8*, 8459.

(53) Apolonski, A.; Roy, S.; Lampe, R.; Sankar Maiti, K. Molecular identification of bio-fluids in gas phase using infrared spectroscopy. *Appl. Opt.* **2020**, *59*, E36–E41.

(54) Mochalski, P.; King, J.; Unterkofler, K.; Amann, A. Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags. *Analyst* **2013**, *138*, 1405–1418.

(55) Baker, J. *The Machine in the Nursery: Incubator Technology and the Origins of Newborn Intensive Care*; Johns Hopkins Introductory Studies in the History Series; Johns Hopkins University Press: Baltimore, MD, 1996.

(56) Kidman, A. M.; Manley, B. J.; Boland, R. A.; Malhotra, A.; et al. Higher versus lower nasal continuous positive airway pressure for extubation of extremely preterm infants in Australia (ÉCLAT): a multicentre, randomised, superiority trial. *Lancet Child & Adolescent Health* **2023**, *7*, 844–851.

(57) Rocha, G.; Soares, P.; Gonçalves, A.; Silva, A. I.; et al. Respiratory Care for the Ventilated Neonate. *Canadian Respiratory Journal* **2018**, *2018*, 1–12.

(58) Maiti, K. S.; Lewton, M.; Fill, E.; Apolonski, A. Sensitive spectroscopic breath analysis by water condensation. *Journal of Breath Research* **2018**, *12*, 046003.

(59) Apolonski, A.; Maiti, K. S. Towards a standard operating procedure for revealing hidden volatile organic compounds in breath: the Fourier-transform IR spectroscopy case. *Appl. Opt.* **2021**, *60*, 4217–4224.

(60) Roy, S.; Maiti, K. S. Baseline correction for the infrared spectra of exhaled breath. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* **2024**, *318*, 124473.

(61) Johnson, T. J.; Sams, R. L.; Sharpe, S. W. The PNNL quantitative infrared database for gas-phase sensing: a spectral library for environmental, hazmat, and public safety standoff detection. *Chemical and Biological Point Sensors for Homeland Defense* **2004**, 159–167.

(62) Gordon, I.E.; Rothman, L.S.; Hill, C.; Kochanov, R.V.; Tan, Y.; Bernath, P.F.; Birk, M.; Boudon, V.; Campargue, A.; Chance, K.V.; Drouin, B.J.; Flaud, J.-M.; Gamache, R.R.; Hodges, J.T.; Jacquemart, D.; Perevalov, V.I.; Perrin, A.; Shine, K.P.; Smith, M.-A.H.; Tennyson, J.; Toon, G.C.; Tran, H.; Tyuterev, V.G.; Barbe, A.; Csaszar, A.G.; Devi, V.M.; Furtenbacher, T.; Harrison, J.J.; Hartmann, J.-M.; Jolly, A.; Johnson, T.J.; Karman, T.; Kleiner, I.; Kyuberis, A.A.; Loos, J.; Lyulin, O.M.; Massie, S.T.; Mikhailenko, S.N.; Moazzen-Ahmadi, N.; Muller, H.S.P.; Naumenko, O.V.; Nikitin, A.V.; Polyansky, O.L.; Rey, M.; Rotger, M.; Sharpe, S.W.; Sung, K.; Starikova, E.; Tashkun, S.A.; Auwera, J. V.; Wagner, G.; Wilzewski, J.; Wcislo, P.; Yu, S.; Zak, E.J. The HITRAN2016 molecular spectroscopic database. *J. Quant. Spectrosc. Radiat. Transfer* **2017**, *203*, 3–69.

(63) Kramida, A.; Ralchenko, Yu.; Reader, J.; and NIST ASD Team. *NIST Atomic Spectra Database* (ver. 5.7.1), [Online]. Available: <https://physics.nist.gov/asd> [2017, April 9]. National Institute of Standards and Technology: Gaithersburg, MD, 2019.

(64) Gelin, M. F.; Blokhin, A. P.; Ostrozhenkova, E.; Apolonski, A.; Maiti, K. S. Theory helps experiment to reveal VOCs in human breath. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* **2021**, *258*, 119785.

(65) Quanjer, P.; Tammeling, G.; Cotes, J.; Pedersen, O.; Peslin, R.; Yernault, J.-C. Lung volumes and forced ventilatory flows. *Eur. Respir. J.* **1993**, *6*, 5–40.

(66) Cheng, W.; Dan, L.; Deng, X.; Feng, J.; et al. *Global Monthly Gridded Atmospheric Carbon Dioxide Concentrations under the Historical and Future Scenarios*; Scientific Data, 2022, 9.

(67) Haick, H.; Broza, Y. Y.; Mochalski, P.; Ruzsanyi, V.; Amann, A. Assessment, origin, and implementation of breath volatile cancer markers. *Chem. Soc. Rev.* **2014**, *43*, 1423–1449.

(68) Amann, A.; Miekisch, W.; Schubert, J.; Buszewski, B.; Ligor, T.; Jezierski, T.; Pleil, J.; Risby, T. Analysis of Exhaled Breath for Disease Detection. *Annual Review of Analytical Chemistry* **2014**, *7*, 455–482.

(69) Nicoll, J.; Cheung, P.-Y.; Aziz, K.; Rajani, V.; O'Reilly, M.; Pichler, G.; Schmölder, G. M. Exhaled Carbon Dioxide and Neonatal Breathing Patterns in Preterm Infants after Birth. *J. Pediatr.* **2015**, *167*, 829–833.

(70) Robbins, R. C.; Borg, K. M.; Robinson, E. Carbon Monoxide in the Atmosphere. *Journal of the Air Pollution Control Association* **1968**, *18*, 106–110.

(71) Rytter, S. W. Special issue on carbon monoxide and exhaled biomarkers in human disease. *J. Breath Res.* **2010**, *4*, 040201.

(72) Kumpitsch, C.; Fischmeister, F. P. S.; Mahnert, A.; Lackner, S.; Wilding, M.; Sturm, C.; Springer, A.; Madl, T.; Holasek, S.; Hogenauer, C.; Berg, I. A.; Schoepf, V.; Moissl-Eichinger, C.; et al. Reduced B12 uptake and increased gastrointestinal formate are associated with archaeome-mediated breath methane emission in humans. *Microbiome* **2021**, *9* DOI: [10.1186/s40168-021-01130-w](https://doi.org/10.1186/s40168-021-01130-w).

(73) Weaver, G. A.; Krause, J. A.; Miller, T. L.; Wolin, M. J. Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. *Gut* **1986**, *27*, 698–704.

(74) Florin, T. H. J.; Zhu, G.; Kirk, K. M.; Martin, N. G. Shared and unique environmental factors determine the ecology of methanogens in humans and rats. *American Journal of Gastroenterology* **2000**, *95*, 2872–2879.

(75) Polag, D.; Keppler, F. Long-term monitoring of breath methane. *Science of The Total Environment* **2018**, *624*, 69–77.

(76) Maiti, K. S.; Apolonski, A. Monitoring the Reaction of the Body State to Antibiotic Treatment against *Helicobacter pylori* via Infrared Spectroscopy: A Case Study. *Molecules* **2021**, *26*, 3474.